High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
55.39M
+29.37%
0.639
-138.94%
52.38M
+15.53%
0.620
-128.05%
60.09M
+26.17%
1.120
+366.67%
Estimates Revision
The market is revising Upward the revenue expectations for Ligand Pharmaceuticals Incorporated (LGND) for FY2025, with the revenue forecasts being adjusted by 23.43% over the past three months. During the same period, the stock price has changed by 13.04%.
Revenue Estimates for FY2025
Revise Upward
+23.43%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1106.12%
In Past 3 Month
Stock Price
Go Up
+13.04%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast LGND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGND is 238.33 USD with a low forecast of 220.00 USD and a high forecast of 275.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 188.500
Low
220.00
Averages
238.33
High
275.00
Current: 188.500
Low
220.00
Averages
238.33
High
275.00
Oppenheimer
Oppenheimer
Outperform
upgrade
$250 -> $275
2025-11-07
Reason
Oppenheimer
Oppenheimer
Price Target
$250 -> $275
2025-11-07
upgrade
Outperform
Reason
Oppenheimer raised the firm's price target on Ligand to $275 from $250 and keeps an Outperform rating on the shares. The firm notes Ligand reported total revenue of $115.5M including $46.6M from royalties, $24.5M from Zelsuvmi's out-licensing, and a $28.6M gain on Pelthos sale. Oppenheimer is bullish on Palvella's two value-unlocking events over next 4 months, which should provide further comfort on Qtorin's commercial opportunity. The firm sees Qtorin as a key driver of future royalties.
Benchmark
Buy
maintain
$175 -> $220
2025-11-07
Reason
Benchmark
Price Target
$175 -> $220
2025-11-07
maintain
Buy
Reason
Benchmark raised the firm's price target on Ligand to $220 from $175 and keeps a Buy rating on the shares after the company reported better-than-expected results for Q3 and increased FY25 guidance.
Stifel
Annabel Samimy
Buy
maintain
$195 -> $220
2025-11-07
Reason
Stifel
Annabel Samimy
Price Target
$195 -> $220
2025-11-07
maintain
Buy
Reason
Stifel analyst Annabel Samimy raised the firm's price target on Ligand to $220 from $195 and keeps a Buy rating on the shares. Consistently exceeding expectations, Ligand posted Q3 revenues of $86.9M an adjusted EPS of $3.09, reflecting a strong win on project financing and diversified royalty portfolio with growth drivers that consistently beat consensus, the analyst tells investors in a research note. The firm added the the company continues to execute across deal types in a capital-hungry financing environment.
RBC Capital
NULL -> Outperform
maintain
$185 -> $234
2025-11-07
Reason
RBC Capital
Price Target
$185 -> $234
2025-11-07
maintain
NULL -> Outperform
Reason
RBC Capital raised the firm's price target on Ligand to $234 from $185 and keeps an Outperform rating on the shares after "another solid quarter" and 2025 guidance raise.
H.C. Wainwright
Buy
maintain
$206 -> $231
2025-11-06
Reason
H.C. Wainwright
Price Target
$206 -> $231
2025-11-06
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Ligand to $231 from $206 and keeps a Buy rating on the shares. The firm cites the company's "strong" Q3 results and continued business development activity for the target boost. The "power of the model continues to deliver the numbers," the analyst tells investors in a research note.
Oppenheimer
Leland Gershell
Outperform
maintain
$167 -> $190
2025-09-03
Reason
Oppenheimer
Leland Gershell
Price Target
$167 -> $190
2025-09-03
maintain
Outperform
Reason
Oppenheimer analyst Leland Gershell raised the firm's price target on Ligand to $190 from $167 and keeps an Outperform rating on the shares. The firm notes Ligand shares have climbed 11% vs. XBI's 9% following their mid-August capital raise likely driven by enthusiasm for the company's model and a lower discount rate including 0.75% convertible debt. Ligand's $460M convert offering yielded $385M net capital, and included a $45M bond hedge which eliminates dilution up to $294/share, along with $15M share repurchase. Management does not expect to change their rate of capital deployment, though Oppenheimer believes this cash balance allows management to be more opportunistic.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Ligand Pharmaceuticals Inc (LGND.O) is 50.02, compared to its 5-year average forward P/E of -9.58. For a more detailed relative valuation and DCF analysis to assess Ligand Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.58
Current PE
50.02
Overvalued PE
143.21
Undervalued PE
-162.37
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
18.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
24.54
Undervalued EV/EBITDA
12.18
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
10.72
Current PS
0.00
Overvalued PS
12.81
Undervalued PS
8.64
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
LGND News & Events
Events Timeline
(ET)
2025-11-07
08:09:20
Pelthos Therapeutics Purchases Xepi Cream from Biofrontera and Ferrer
2025-11-06 (ET)
2025-11-06
07:19:02
Ligand increases FY25 adjusted EPS forecast to $7.40-$7.65, up from $6.70-$7.00
2025-11-06
07:17:01
Ligand Announces Q3 Adjusted EPS of $3.09, Exceeding Consensus Estimate of $1.89
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/a253b53282e43e017ca0e69d726f9e750fb195b396892a99ad5743dc0a4e0b93.png)
Preview
9.5
11-10GlobenewswireOrchestra BioMed Announces Financial Results for Q3 2025 and Shares Recent Business Developments
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/newsfilter.png)
Preview
8.5
11-07NewsfilterPelthos Therapeutics Purchases Xepi® (ozenoxacin) Cream, 1%, and Reveals $18 Million Private Convertible Notes Funding
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/43a0e4d2a5cccb5a5d1fe475895d45aa42a68852f71a5ed25c6ffd4ac386e9d1.png)
Preview
7.5
11-07BenzingaEXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support
Sign Up For More News
People Also Watch
FAQ
What is Ligand Pharmaceuticals Inc (LGND) stock price today?
What is Ligand Pharmaceuticals Inc (LGND)'s business?
What is the price predicton of LGND Stock?
What is Ligand Pharmaceuticals Inc (LGND)'s revenue for the last quarter?
What is Ligand Pharmaceuticals Inc (LGND)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Ligand Pharmaceuticals Inc (LGND)'s fundamentals?
How many employees does Ligand Pharmaceuticals Inc (LGND). have?